Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology

Since 2016, results from physiologically based pharmacokinetic (PBPK) analyses have been routinely found in the clinical pharmacology section of regulatory applications submitted to the US Food and Drug Administration (FDA). In 2018, the Food and Drug Administration's Office of Clinical Pharmac...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacology Vol. 60 Suppl 1; p. S160
Main Authors Zhang, Xinyuan, Yang, Yuching, Grimstein, Manuela, Fan, Jianghong, Grillo, Joseph A, Huang, Shiew-Mei, Zhu, Hao, Wang, Yaning
Format Journal Article
LanguageEnglish
Published England 01.10.2020
Subjects
modeling and simulation
PBPK
drug-drug interactions
pharmacokinetics and drug metabolism
clinical pharmacology (CPH)
MIDD (model-informed drug development)
Online AccessGet more information

Cover

More Information
Summary:Since 2016, results from physiologically based pharmacokinetic (PBPK) analyses have been routinely found in the clinical pharmacology section of regulatory applications submitted to the US Food and Drug Administration (FDA). In 2018, the Food and Drug Administration's Office of Clinical Pharmacology published a commentary summarizing the application of PBPK modeling in the submissions it received between 2008 and 2017 and its impact on prescribing information. In this commentary, we provide an update on the application of PBPK modeling in submissions received between 2018 and 2019 and highlight a few notable examples.
ISSN:1552-4604
DOI:10.1002/jcph.1767